-
Interim NADIM ADJUVANT Data Suggest Adjuvant Chemo-IO May Reduce Recurrence Risk in Patients Following Complete Resection
-
Final FLAURA2 OS Data Show Osimertinib Plus Chemo Offers Benefit Compared with Monotherapy
-
Potential Impact of GLP1-RAs on TKI-induced Weight Gain in Patients with NSCLC
-
No “Known” Risk Factors: The Health Consequences of Radiation Therapy
-
Discussion Covered Updates, Strategies, and Controversies in Lung Cancer Staging
-
No PFS, OS Benefit Seen in Final Results from PACIFIC-2
-
WCLC Attendees Hear Preview of Proposed Changes for the 9th Edition of the TNM Staging Classification for Thoracic Cancers
-
Treatment of Immunotherapy-Related Dermatologic Toxicities: An Interview with Dr. Mario Lacouture
-
A Holistic Approach to Patient Care
-
Telehealth Struggles to Find Permanent Footing After Rapid Growth During Pandemic
The ILCN is aware that the situation with telehealth differs across regions and that lack of access to technology is a huge obstacle. We would love to hear from IASLC members around the globe about your experiences. Please email us at [email protected].
-
Therapeutic Vaccine Development in Lung Cancer: Update and Recent Advances
Most cancer immunotherapies currently in development aim to stimulate antitumor T-cell responses either by adoptive transfer of in vitro expanded native or genetically modified T lymphocytes targeting malignant cells,1 ,2 administration of neutralizing monoclonal antibodies (mAb) specific to T-cell inhibitory receptors, such as cytotoxic T-lymphocyte-associated antigen-4 (CTLA-4) and programmed death-1 (PD-1),3 ,4 ,5 ,6 ,7…
-
Radiotherapy Inaccessibility in Lung Cancer Care: An Ongoing Crisis
A leading cause of mortality worldwide, cancer was tied to nearly 10 million deaths in 2020.1 Lung cancer has remained unchallenged for more than 30 years as the most commonly diagnosed malignancy and the leading cause of cancer mortality worldwide, accounting for up to 1.8 million deaths per year.2 ,3 Treatment for lung cancer depends…
-
Economics of Locally Advanced Lung Cancer Before and During COVID-19 Pandemic: A Perspective for Developing Countries
Since December 2019, the world has been mired in a pandemic that has displaced other 21st-century health priorities for many populations. The social significance and speed of contagion from COVID-19 have altered criteria for public health prioritization, to the detriment of other health problems including noncommunicable diseases, which are recognized as the leading cause of…
-
More Than a Partnership: How Oncogene-Driven Patient Groups Are Mobilizing the Global Community to Drive Research
It has been just over a year since we reported how oncogene-driven patient advocacy groups are disrupting the research paradigm in lung cancer.1 We have indeed come a long way since the discovery of the first EGFR mutation in lung cancer in 2004.2 ,3 Even amid the challenges of the global COVID-19 pandemic, the lung…
-
Transbronchial Microwave Ablation of Malignant Lung Nodules: Outcomes, Challenges, and Perspective
With increasing availability of CT scans and strong evidence for the utility of low-dose CT screening in high-risk populations,1 an increasing number of small lung nodules are being incidentally discovered. Many are small, subsolid, and may harbor premalignant or early-stage tumors. Local treatment of early primary lung cancers and lung oligometastases is gaining popularity, especially…
-
Ablation Techniques for Lung Nodules: Percutaneous or Transbronchial Approach?
Surgical resection is the most effective treatment for patients with early-stage NSCLC.1 However, approximately 25% of these patients do not undergo resection, usually because of underlying comorbidities precluding surgery or because of patient refusal.2 For these patients and others with medically inoperable conditions, several guidelines recommend stereotactic body radiotherapy.3 However, the indication of stereotactic body…
-
Savolitinib Approved in China for MET-Positive NSCLC
June 23, 2021—Savolitinib was approved in China for treatment of patients with NSCLC with MET exon 14 skipping alterations whose disease has progressed following systemic treatment or who are unable to receive chemotherapy. The National Medical Products Administration based its approval on a phase II trial of 70 patients with NSCLC that included a…
-
Durvalumab Plus Chemotherapy Approved in China as First-Line Management of Extensive-stage SCLC
July 19—The National Medical Products Administration in China approved durvalumab in combination with standard-of-care platinum chemotherapy (as defined as etoposide plus carboplatin or cisplatin) for the first-line management of extensive-stage SCLC. This approval joins those in more than 55 countries for this indication. The approval was based on the CASPIAN phase III trial, which demonstrated…
-
Dr. Patrick Forde Discusses Excitement Around Neoadjuvant Immunotherapy for Lung Cancer
CheckMate-816 made quite a splash at both the AACR Annual Meeting 2021 and the 2021 ASCO Annual Meeting’s virtual podium, and the accompanying article by Patrick Forde, MD, explains why. Dr. Forde, who is director of the Thoracic Oncology Clinical Research Program and associate professor of Oncology at Johns Hopkins Medicine in Baltimore, MD, met…